# US 12,005,080 B2 · Method for promoting proliferation of immune cells > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,005,080 B2 - Document ID: US12005080B2 - Status: Granted - Kind: B2 - Application number: 17/040,865 - Filed: 2019-03-25 - Published: 2021-04-15 - Granted: 2024-06-11 - Earliest claimed: 2018-03-26 - Assignees: Oricell Therapeutics Co., Ltd. - Applicants: Oricell Therapeutics Co., Ltd. - Inventors: Youguo Ling; Hao Guo; Xiaowen He; Haili Ma; Huijiao Li; Huajing Wang; Bi Ying; Huanfeng Yang - Web page: https://patentgrep.com/patent/US12005080B2 ## CPC - C12N 5/0636: {T lymphocytes} - A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/31: Chimeric antigen receptors [CAR] - A61K 40/4261: {Proteoglycans, e.g. glypican, brevican or CSPG4} - A61P 35/00: Antineoplastic agents - C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} - C12N 15/86: Viral vectors - A61K 2239/31: characterized by the route of administration - A61K 2239/38: characterised by the dose, timing or administration schedule - A61K 2239/53: Liver - C07K 14/7051: {T-cell receptor (TcR)-CD3 complex} - C07K 2319/03: containing a transmembrane segment - C12N 2740/15043: viral genome or elements thereof as genetic vector - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells. ## Claims ### Claim 1 A genetically modified human immune cell, wherein the genetic modification up-regulates an expression of a low density lipoprotein receptor-associated protein or fragment thereof in the genetically modified immune cell, wherein the low density lipoprotein receptor-associated protein is low density lipoprotein receptor-associated protein 6 or the low density lipoprotein receptor-associated protein 5, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an intracellular region of the low density lipoprotein receptor-associated protein, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an amino acid sequence as set forth in any one of SEQ ID NO: 22, 24, 26, and 28, or an amino acid sequence having at least 80% homology thereof. ### Claim 2 (depends on 1) The genetically modified immune cell according to claim 1, which expresses a chimeric antigen receptor (CAR) or a T cell receptor (TCR). ### Claim 3 (depends on 1) The genetically modified immune cell according to claim 1, wherein the low density lipoprotein receptor-associated protein or fragment thereof is derived from a human. ### Claim 4 (depends on 1) The genetically modified immune cell according to claim 1, wherein the low density lipoprotein receptor-associated protein 6 or fragment thereof further comprises an transmembrane region of the low density lipoprotein receptor-associated protein 6. ### Claim 5 (depends on 1) The genetically modified immune cell according to claim 1, wherein the low density lipoprotein receptor-associated protein 5 or fragment thereof further comprises an transmembrane region of the low density lipoprotein receptor-associated protein 5. ### Claim 6 A genetically modified human immune cell, wherein the genetic modification up-regulates an expression of a low density lipoprotein receptor-associated protein or fragment thereof in the genetically modified immune cell, wherein the low density lipoprotein receptor-associated protein is low density lipoprotein receptor-associated protein 6 or the low density lipoprotein receptor-associated protein 5, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an intracellular region of the low density lipoprotein receptor-associated protein, wherein a nucleic acid molecule encoding the low density lipoprotein receptor-associated protein or fragment thereof comprises a nucleic acid sequence as set forth in any one of SEQ ID NO: 21, 23, 25, and 27. ### Claim 7 (depends on 1) A method for preparing the genetically modified immune cell of claim 1, comprising: up-regulating an expression of the low density lipoprotein receptor-associated protein or fragment thereof in the genetically modified immune cell. ### Claim 8 (depends on 7) The method according to claim 7, further comprising: introducing into the genetically modified immune cell a vector up-regulating the expression of the low density lipoprotein receptor-associated protein or fragment thereof. ### Claim 9 (depends on 8) The method according to claim 8, wherein the vector is at least one selected from the group consisting of a retroviral vector, a lentiviral vector, and a transposon plasmid.